Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study (2022)
Attributed to:
G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2665-9913(21)00333-7
Publication URI: http://dx.doi.org/10.1016/s2665-9913(21)00333-7
Type: Journal Article/Review
Parent Publication: The Lancet Rheumatology
Issue: 1